Is There Clinical Trial Evidence for PRP in Fertility?

If you’ve spent any time researching fertility options beyond standard IVF, you’ve probably come across platelet-rich plasma, or PRP. It’s one of the more interesting frontiers in reproductive medicine because it uses a patient’s own blood, it’s being actively studied at major fertility centers, and early research has produced some encouraging findings for women who’ve been told their options are limited.

Like most emerging treatments, the research is still catching up to the enthusiasm. PRP is not FDA-approved as a fertility treatment, and the evidence from clinical trials so far is a mix of encouraging early findings and important unanswered questions. That’s not unusual for an emerging PRP fertility treatment, and it’s exactly why understanding what the studies actually show, and what they’re still figuring out, is worth ten minutes of your time before you decide anything.

What Is PRP, and Why Are Fertility Researchers Studying It?

PRP is created by drawing a patient’s own blood, spinning it in a centrifuge, and concentrating the platelets, which carry growth factors tied to tissue repair and blood vessel formation. In fertility research, PRP has been injected directly into the ovaries, where scientists theorize it may support the ovarian microenvironment and potentially stimulate residual follicular activity in women whose reserve has declined. This specific application is often called intraovarian PRP or ovarian PRP therapy.

PRP Fertility Clinical Trials: What the Research Shows

Before the first published randomized controlled trial of intraovarian PRP in women with poor ovarian response, several studies had already reported encouraging findings using PRP for women with a poor response to fertility treatment, from improved ovarian reserve markers to documented live births. Findings like these are a big part of why PRP generated so much interest among reproductive specialists in the first place, and why a growing number of fertility centers now offer it as part of an individualized treatment plan.

Science moves in stages, though, and randomized controlled trials can provide stronger evidence about whether an observed effect is actually caused by the treatment rather than by natural variation or other factors. The first one for ovarian PRP, called PROVA, followed a specific group closely: women aged 18 to 37 with an established history of poor ovarian response after IVF. The trial concluded that PRP did not improve mature oocyte yield or other IVF outcomes in this population, and its authors said the findings did not support using intraovarian PRP in this group.

Research here is still very much in motion. Another randomized trial, PRP4POA (NCT04278313), is studying the effects of intraovarian PRP on ovarian function in women with ovarian aging, and a 2025 critical review in Biomedicines provides a useful overview of where the evidence currently stands: encouraging signals exist, and larger, multicenter trials are the natural next step toward turning those signals into standardized clinical guidance. The table below breaks down the specific studies behind this summary.

PRP Fertility Studies at a Glance

Why the Early Studies and the First Trial Read Differently

This nuance matters, and it’s worth understanding rather than skipping past. The earlier positive studies did not use randomized controlled designs, which means it’s harder to fully separate a treatment effect from other things happening at the same time, like patients simply trying again or natural month-to-month variation. PROVA's design controlled for that, which is valuable, but it also means its result speaks most directly to the specific group it studied: women under 38 with a defined history of poor response, most often meaning at least two prior IVF cycles with three or fewer mature oocytes despite maximum stimulation.

None of this makes the earlier results meaningless. It means researchers now have a clearer roadmap for the questions still worth answering, including whether outcomes differ by age or diagnosis, such as premature ovarian insufficiency or menopause, which were represented in some of the earlier case reports, or by PRP preparation method. That's exactly what trials like PRP4POA are built to explore. Across this research, the underlying question has always been whether PRP can support ovarian function that's still present, which is why studies generally focus on women with some measurable follicular activity rather than women with more advanced loss of ovarian function.

Age is a genuinely important piece of this picture. PROVA, the one completed RCT, enrolled women under 38, so its result speaks most directly to that group. But several of the earlier non-randomized studies included a wider age range: the 510-patient cohort spanned women aged 30 to 45, and the case series on natural conceptions included two women with premature ovarian failure, aged 40 and 27, and one menopausal woman aged 46.

What This Means If You’re Considering PRP for Fertility

PRP research is moving quickly; the field has real momentum, and where the science currently stands is that it looks promising for some patients while researchers work out precisely who benefits most and under what protocol. That uncertainty is a reason to discuss the potential benefits, limitations, costs, and alternatives with a fertility specialist before deciding whether to pursue it.

A good next step is asking your specialist what the current evidence shows for someone with your specific diagnosis, age, and history, not just for PRP as a general category. Ask about the preparation method and injection protocol they use, since results have varied across published studies.

Conclusion

PRP for fertility is a genuinely promising area of reproductive medicine that’s still being actively refined through research. Early observational studies produced encouraging findings, but the first published randomized trial of intraovarian PRP in women with poor ovarian response did not show a benefit in its study population. Ongoing research is examining whether PRP could have a role in other patient groups or under different protocols. That uncertainty is an important part of the current evidence. If you’re considering PRP, discuss the available research, potential risks, alternatives, and whether the treatment is appropriate for your specific situation with a qualified fertility specialist.